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Association of tumour vasculature with tumour
progression and overall survival of patients with non-
early gastric carcinomas
N Tanigawa, H Amaya, M Matsumura and T Shimomatsuya
The Second Department of Surgery, Fukui Medical School, Matsuoka-Cho, Yoshida-Gun, Fukui Prefecture 910-11, Japan
Summary In order to investigate the relationship between intratumoral vasculature and progression of gastric carcinomas and between
vessel counts and survival of patients with non-early gastric carcinoma, we counted the intratumoral microvessels and compared their
numbers with clinicopathological parameters, as well as with the patients' survival. Microvessels were stained with anti-CD34 monoclonal
antibody before counting by microscopy (x200). In a group of 181 patients who had undergone tumour resection and were followed for more
than 24 months the vessel counts for 83 patients with stage IV disease were significantly higher than those for patients with any other stage
of disease. Among various clinicopathological variables, haematogenous metastasis, lymph node metastasis, peritoneal metastasis, stage IV
disease and non-curative resection were more frequent in the patients with highly vascularized tumours (intratumoral vessel count > 155)
than in those with less vascularized tumours. As a classification of stage IV disease such as haematogenous or peritoneal metastasis
generally indicates non-curative resection, it can be considered that the development of stage IV disease is associated with the increase in
tumour angiogenesis. Both univariate and multivariate analyses showed that the intratumoral vessel count was significantly predictive of
overall survival, when tested as either a continuous or dichotomous variable. Cox hazards model analysis showed that the vessel count was
one of the significant and independent prognostic variables. Patients with highly vascularized tumours were significantly more likely to die
than those with less vascularized tumours. Assessment of tumour vasculature may therefore be important, not only for its prognostic value,
but also as it may help to predict responses to angiogenesis-inhibiting agents.
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It is clinically valuable to identify those patients with gastric carci-
noma at significant risk for recurrence who would benefit from
treatment with adjuvant therapy. The need to individualize adjuvant
therapy has resulted in an intensive search for newer and more reli-
able prognostic factors for gastric carcinomas. However, as far as
we know, there is no parameter more suitable than the classification
of disease stages to predict the patient's outcome. Whereas post-
operative 5-year survival rates are 90-95% for early gastric carci-
nomas, which are confined to mucosal or submucosal layer (tl),
only 20-40% of the patients with non-early stage carcinoma are
expected to survive for 5 years or more (Japanese Research Society
for Gastric Cancer, 1993). Recently, assessment oftumour vascula-
ture has shown promise as a reliable prognostic marker in patients
with a variety of malignancies, including malignant melanoma
(Srivastava et al, 1986), breast carcinoma (Weidner et al, 1991; Toi
et al, 1993), ovarian carcinoma (Hollingsworth et al, 1995), non-
small-cell lung carcinoma (Macchiarini et al, 1992) and prostatic
carcinoma (Wakui et al, 1992). We previously demonstrated that
the intensity ofthe angiogenic response correlates with not only the
overall survival rate, but also the development of metachronous
haematogenous metastasis in the patients with gastric carcinomas
who had undergone curative resection (Tanigawa et al, 1996).
Therefore, in the present study, we attempted to clarify whether the
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extent of tumour vasculature would be prognostically important
even when the study only included patients with non-early gastric
carcinomas, some of whom had undergone non-curative resection.
MATERIALS AND METHODS
Patient characteristics
A total of 181 patients with a non-early stage ofgastric carcinoma
and who had undergone gastrectomy at our institution from
October 1983 to December 1993 were studied. Preoperative endo-
scopic biopsies revealed that all the tumours were adenocarci-
nomas. Pathological diagnosis of each tumour was performed by
pathologists in our hospital according to the General Rules for
Gastric Cancer (Japanese Research Society for Gastric Cancer,
1993). Survivors were followed up for more than 2 years after
surgery. There was no patient with other previous or concomitant
primary cancer. The distribution ofclinicopathological data for the
entire population is listed in Table 1. Patients had received neither
chemotherapy nor radiation therapy before surgery. A total of 107
patients (59%), less than 70 years old, were treated with tegaful (2-
tetra-hydrofuryl)-5-fluorouracil at 600 mg day-' for as long as
possible, up to 2 years after surgery. Each patient was examined at
2- or 3-monthly intervals in the outpatient clinic. The patients who
failed to attend the clinic were traced by telephone. If the patient
had died, the date and cause ofdeath were recorded. Tumour spec-
imens were fixed in 10% buffered formalin and embedded in
paraffin. Histological grading was performed on haematoxylin and
eosin (H&E)-stained sections.
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Highlighting endothelial cells
Immunohistochemical studies were performed with the method
previously described (Tanigawa et al, 1996). Briefly, on formalin-
fixed and paraffin-embedded tissue, the avidin-biotin immunoper-
oxidase complex technique was applied for highlighting the
endothelial cells. One representative paraffin block from each
case, in which a viable tumour was present, was used for this
study. Sections (4-6 gm thick) mounted on glass slides were
dewaxed in xylene, rehydrated in ethanol and then incubated with
3% hydrogen peroxide for 5 min. After washing with phosphate-
buffered saline (PBS), they were incubated in 10% normal bovine
serum for 5 min followed by incubation overnight with anti-CD34
monoclonal antibody (QB-END/10, Novocastra, Newcastle, UK)
at a 1:25 dilution. A biotinylated goat anti-mouse immunoglobulin
(Dako LSAB kit, Dako Japan, Kyoto, Japan) was used as a
secondary antibody. Peroxidase-conjugated avidin (Dako Japan)
was used at a dilution of 1:500. Finally, 0.02% diaminobenzidine
and 1% hydrogen peroxide (Dako Japan) in PBS were used as the
substrate. The sections were counterstained with haematoxylin.
Assessment of tumour vasculature
Slides were examined under low power (40x) to identify the region
of highest vessel density. For each slide, the five most vascular
areas within the tumour mass were chosen. A 200x field in each of
these five areas was counted, and the average counts of the five
fields were recorded. A vessel lumen was not required for identifi-
cation of a microvessel; single cells or cell clusters were counted.
Large vessels with thick muscular walls or with lumina greater
than 50 gm were excluded from the count. The microvessels were
counted simultaneously by two investigators, MM and HA, who
had no knowledge of the other prognostic factors and/or clinical
outcomes, using a double-headed light microscope simultaneously.
Statistical evaluation
We analysed the intratumoral vessel counts in two ways. First, we
assessed vessel counts as a continuous variable and second as a
dichotomous variable, which was dichotomized at a median
number ofvessel counts. The clinical characteristics ofthe patients
in relation to the vessel counts were compared and checked by the
chi-square test. Intratumoral vessel densities among various
disease stages were compared and checked by Welch's t-test. The
patterns of overall survival were estimated by means of the
Kaplan-Meier method and their statistical differences were
analysed by the generalized Wilcoxon test. The role of each of the
prognostic variables (univariate analysis) and their joint effects
(multivariate analysis) was evaluated. In the multivariate analysis,
all variables with odds ratios significantly different from 1.0 in the
univariate analysis were considered. For all statistical analyses, the
Statistical Analysis System for personal computers (SAS Institute,
Cary, NC, USA) was used, with significance having been defined
as P<0.05.
RESULTS
Clinical outcome of all patients
Fifty-four of 181 patients (30%) have survived for a mean survival
length of 49 months, ranging from 24 to 120 months. The
remaining 127 (70%) died between 1 and 77 months (mean 17
months) after surgery. Peritoneal metastasis occurred in 79
patients (44%); 41 metastases were found at surgery and 38 devel-
oped after surgery. Haematogenous metastasis occurred in 38
Table 1 Clinicopathological parameters in 181 non-early gastric carcinomas
Age (years)
Mean
Range
Sex
Male
Female
Borrmann classification
1
2
3
4
Uncl.a
Tumour histologyb
Pap
Tub
Poor
Undiff
Tumour depthc
t2
t3
t4
Lymphatic invasiond
IyO
lyl
Iy2
Iy3
Vessel invasione
vO
vl
v2
v3
Lymph node metastasis'
nO
nl
n2
n3
n4
Stage of disease
IV
Extent of gastrectomy
Distal
Proximal
Total
Surgical curability
Curative resection
Non-curative resection
65
26-87
121 (67%)
60 (33%)
14 (8%)
52 (29%)
78 (43%)
27 (15%)
10 (6%)
19 (11%)
44 (24%)
69 (38%)
49 (27%)
72 (40%)
79 (44%)
30 (16%)
20 (11%)
28 (15%)
108 (60%)
25 (14%)
59 (33%)
56 (31%)
58 (32%)
8 (4%)
36 (20%)
46 (25%)
48 (27%)
20 (11%)
31 (17%)
22 (12%)
20 (11%)
56 (31%)
83 (46%)
105 (58%)
8 (4%)
68 (38%)
119 (66%)
62 (34%)
aUncl.; unclassified type, being impossible to be classified as Borrmann 1 to
4, bPap, papillary; Tub, tubular; Poor, poorly differentiated; Undiff,
undifferentiated. 12, invading the muscularis or the subserosa, t3, penetrating
the serosa; t4, invading adjacent organs. dlyO, no lymphatic invasion; lyl,
slight degree of lymphatic vessel invasion; Iy2, moderate degree of lymphatic
vessel invasion; Iy3, extensive degree of lymphatic vessel invasion evO, no
venous vessel invasion; vi, slight degree of venous vessel invasion; v2,
moderate degree of venous vessel invasion; v3, extensive degree of venous
vessel invasion. 'nO, no regional lymph node metastasis; ni, n2, n3, n4,
metastasis in group 1, 2, 3, 4 lymph node stations respectively.
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hypovascular tumours and those with hypervascular tumours
Variable Hypovascular (n=90) Hypervascular (n=91) P-value
(0) (%)
179 + 69
Age
<65
>65
Sex
Male
Female
45 (52)
45 (47)
57 (47)
33 (55)
Borrmann classification
1, 2 32 (50)
3, 4, unclassifieda 58 (50)
Tumour histology
Well differentiated 47 (57)
Poorly differentiated 43 (44)
II IlIl IV
(n= 22) (n 20) (n= 56) (n= 83)
Stage
Figure 1 Intratumoral vessel counts for each disease stage. Vessel counts
for stage IV disease were significantly higher than those for any other stage
of disease. *P=0.011, **P=0.003, ***P=0.011
Depth of penetrationb
t2
t3, t4
Lymphatic invasionc
IyO, lyl
Iy2, Iy3
Venous vessel invasiond
vO, vl
v2 v3
Adjuvant chemotherapy
Negative
Positive
41 (56)
49 (45)
25 (51)
65 (49)
64 (54)
26 (41)
55 (51)
35 (47)
41 (48)
50 (53)
64 (53)
27 (45)
32 (50)
59 (50)
36 (43)
55 (56)
NS
NS
NS
NS
NS
NS
NS
NS
32 (44)
59 (55)
24 (49)
67 (51)
54 (46)
37 (59)
52 (49)
39 (53)
patients (21 (4); 18 liver metastases were found at surgery and 20
haemnatogenous imletastases developed alter surgery (ten liver, four
lung, two bone. two bone marr-ow and two brain). Both peritoneal
and haematogenous metastases occur-r-ed in ten patients (6%): peni-
toneal and liverimetastases were found in nine patients at surgery,
and peritoneal and lunlg metastases developed after surgery in one
patient. Lymph node metastases werc founld in 144 paticnts (80%()
at surgery.
Comparison of tumour vasculature among various
clinicopathological factors
Intratumoral vessel counlts for a total of 181 patients wer-e 158 +
75 mean plus or minus standard deviation (m.s.d.) (median 155).
Each paticnt was assigned to one ol the following stage groups
according to the clinicopathological findings of the resected
turniours 22 paticuts (12%/C) with stage I disease, 20 (116C) with
stage II, 56 (31%S. ) with stage III and 83 (46%c) with stage IV.
Intr-atumor-al vessel counts for relevant disease stages wer-e 143 +
65 MSD foor stage I disease, 124 + 69 MSD for stage II, 144 + 84
MSD for stage III, and 179 + 69 MSD for stage IV. Vessel couints
for stage IV disease were significantly higher than those for any
other stage of disease (FigLUre 1). A median value of 155 was taken
as the cut-off point for discrimination of the 181 patients into two
subgroups: 91 patients with hypovascular- tumours and 90 with
hypervascular tLumours. Among the clinicopathological var-iables
exa.mined, age, sex, Borrmnann classification, tumour histology,
depth of penetration lymphatic invasion, venous vessel invasion
anid adjuvant chemotherapy were equally distributed among thcse
two subgroups. However, haematogenous metastasis, lymph node
metastasis, peritoneal metastasis, stage IV disease and non-curative
resection were more lrequent in the hypervascular group (Table 2).
Peritoneal metastasis
Negative
Positive
Lymph node metastasise
nO, nl, n2 E
n3, n4
53 (58)
37 (41)
69 (53)
21 (41)
Haematogenous metastasis
Negative 81 (61)
Positive 9 (19)
Stage of disease
Stage
Stage II
Stage Ill
Stage IV
Surgical curability
Curative
Non-curative
14 (64)
14 (70)
34 (61)
28 (34)
69 (58)
21 (34)
39 (42)
52 (59)
12 (47)
30 (59)
52 (39)
39 (81)
8 (36)
6 (30)
22 (39)
55 (66)
50 (42)
41 (66)
P=0.031
NS
P<0.00000 1
P= .001
P=0.002
See Table 1 for abbreviations.
Correlation between vessel counts and overall survival
Univariate analysis
We found that the intratumnoral vessel Counts sionificantly
predicted overall suirvival when evaluated as either a continuous
or dichotomous variable (P=0.0001 and P=0.0001 respectively)
(Table 3). The odds of death increase with the intratumiior-al
microvessel counts and an average vessel count of less than 155
per 200x field suggcsted a bettei- survival. The survival ratcs of the
two subgroups were calculated as follows using the Kaplan-Meier
method: 50c%c + 6%/c standard error of the mean (s.e.m.) ofthe hypo-
vascular group, but only 11 cc + 4% s.e.m. of the hypervascular
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Table 3 Univariate analysis of the prognostic value of various
cliniopathological factors for predicting overall survival
Variable Odds 95% Confidence Wald chi- P-value
ratios limits square
Intr&tumoral vessels
Continuous variable 1.008 1.005-1.010 42.36 0.0001
<155 vs> 155 3.099 2.109-4.553 33.17 0.0001
Age
< 65 vs.65 1.035 0.722-1.485 0.04 0.85
Sex
Male vs Female 0.822 0.558-1.209 0.99 0.32
Histological differentiation
Well vs poorly 1.319 0.918-1.896 2.24 0.13
Lymphatic invasion
lyO-1 vsly2-3 1.960 1.248-3.079 8.53 0.0035
Venous vessel invasion
v0-1 vsv2-3 2.686 1.848-3.904 26.80 0.0001
Tumour depth
t2 vst3-4 1.753 1.195-2.570 8.23 0.0041
Borrmann classification
Type 1-2 vstype 3-uncl. 1.642 1.106-2.437 6.06 0.0138
Peritoneal metastasis
Negative vs positive 4.169 2.794-6.222 48.84 0.0001
Haematogenous metastasis
Negative vs positive 2.221 1.514-3.259 16.65 0.0001
Lymph node metastasise
Negative vspositive 2.596 1.528-4.411 12.45 0.0004
Surgical curability
Curative vs non-curative 3.525 2.394-5.190 40.71 0.0001
See Table 1 for abbreviations.
Table 4 Multivariate analysis showing independent predictors of overall
survival according to the Co hazards model
Variable Odds 95% Confidence Wald chi- P-value
ratios limits square
Model 1
Intratumoral vessels
Continuous variable 1.005
Lymphatic invasion
IyO-1 vsly2-3 1.008
Venous vessel invasion
vO-1 vsv2-3 2.469
Tumour depth
t2vst3-4 0.992
Borrmann classification
Type 1-2 vstype 3-uncl. 1.272
Peritoneal metastasis
Negative vs positive 5.267
Haematogenous metastasis
Negative vs positive 3.056
Lymph node metastasis
Negative vs positive 1.883
Surgical curability
Curative vs non-curative 1.330
Model2
Intratumoral vessels
<155 vs 2 155 1.682
Lymphatic invasion
lyO-1 vsly2-3 1.056
Venous vessel invasion
vO-1 vs 2-3 2.473
Tumour depthc
t2 vs t3-4 0.947
1.002-1.008 9.99 0.0016
0.565-1.799 0.00 0.98
1.511-4.034 13.01 0.0003
0.650-1.512 0.97 0.97
0.793-2.041 0.99 0.32
3.178-8.729 41.53 0.0001
1.762-5.302 15.79 0.0001
1.020-3.257 3.07 0.063
0.766-2.309 1.03 0.31
1.078-2.625 5.25 0.0219
0.586-1.903 0.03 0.85
1.501-4.073 12.64 0.0004
0.616-1.456 0.06 0.80
60 lo 60 ~ X
'Ft 50
t 40
C) 30
20
10
0 1 2 3 4 5
Post-operative years
Figure 2 Survival curves for patients dichotomized according to
intratumoural vessel counts. Survival of 90 patients with less vascularized
tumours (< 155 per 200 field) (dark line) was significantly longer than that of
91 patients with highly vascularized tumours (2 155 per 200 field) (light line)
(P<0.0001 by generalized Wilcoxon test)
group survived for 5 years (Figure 2). In addition to vessel
counts, other prognostic factors found to be significantly associ-
ated with overall survival were peritoneal metastasis (P=0.0001),
haematogenous metastasis (P=0.0001), lymph node metastasis
(P=0.0004), depth of penetration (P=0.0041), Borrmann classifi-
cation (P=0.0138), venous vessel invasion (P=0.0001), lymphatic
Borrmann classification
Type 1-2 vs type 3-uncl. 1.348
Peritoneal metastasis
Negative vs positive 5.254
Haematogenous metastasis
Negative vs positive 3.274
Lymph node metastasis
Negative vs positive 1.712
Surgical curability
Curative vs non-curative 1.329
0.843-2.157 1.55 0.21
3.141-8.789 39.93 0.0001
1.880-5.702 17.551 0.0001
0.882-3.323 2.52 0.11
0.760-2.326 0.99 0.31
See Table 1 for abbreviations.
vessel invasion (P=0.0035), and surgical curability (P=0.0001).
Patient age, sex and tumour histology were not associated with
overall survival (Table 3).
Multivariate analysis
Multivariate analysis of the joint effect of combining the vessel
count with the otherprognostic factors showed that the vessel count
was identified as one ofthe significant and independent prognostic
variables, in addition to haematogenous metastasis, peritoneal
metastasis and venous vessel invasion. The intratumoral micro-
vessel count was an independent and significant prognostic factor
when tested as either a continuous or dichotomous variable
(P=0.0016 and P=0.0219 respectively) (Table 4). Patients with
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highly vascularized tumours were more likely to die than those with
less vascularized tumours. Lymph node metastasis, Borrmann clas-
sification, depth of penetration, lymphatic invasion and surgical
curability, which were found to be prognostically significant by the
univariate analysis, failed to retain an independent and significant
value for overall survival in the multivariate analysis (Table 4).
DISCUSSION
Most of the studies measuring microvessel counts in the human
tumours used antibody against von Willebrand factor - related
antigen to highlight microvessels (Bosari et al, 1992; Weidner et
al, 1992; Toi et al, 1993; Maeda et al, 1995). Although this is a reli-
able technique, variability in staining and lack of reproducibility
may produce misleading results (Hall et al, 1992; Horak et al,
1992; Van Hoef et al, 1993). Recently, a monoclonal antibody
against CD34 (human progenitor cell antigen) has been demon-
strated to stain blood vessels in both normal and malignant tissues
(Anthony et al, 1991). As consistent with other reports (Graham et
al, 1994; Hollingsworth et al, 1995), immunostaining microvessels
with anti-CD34 antibody provided a more sensitive and accurate
measure of tumour angiogenesis and provided even better prog-
nostic information than that produced by anti-von Willebrand
factor antibody in our previous study (Tanigawa et al, 1996), the
data ofvessel counts in the present study were taken from the anti-
CD34 staining.
The chi-square analyses demonstrated that haematogenous
metastasis, peritoneal metastasis, stage IV disease and non-cura-
tive resection were more frequent in the hypervascular group than
in the hypovascular group, whereas other clinicopathological vari-
ables were equally distributed among these two subgroups. A clas-
sification of stage IV disease includes not only peritoneal and/or
visceral metastasis, but also lymph node metastasis extending to
group 4 nodes (n4) or direct tumour extension to adjacent struc-
tures or organs (t4) (Japanese Research Society for Gastric Cancer,
1993). As each of those classifications generally indicates non-
curative resection, the aforementioned findings seem to be concor-
dant with our other result that the intratumoral vessel counts in the
stage IV disease were significantly higher than those in any other
stage ofdisease. Accordingly, the development of stage IV disease
can be interpreted in association with the increase in tumour angio-
genesis. There is considerable experimental evidence to indicate
that angiogenesis is an important element in growth and metastatic
dissemination of solid tumours, although neovascularization is
only one of the requirements (Gould et al, 1983; Folkman, 1986;
Liotta et al, 1989; Folkman, 1990). Therefore, in this study, we
have found that the development of stage IV disease of human
gastric carcinoma is accompanied by an increase in capillary
formation to supply the tumour mass and to provide a possible
route for metastasis.
Sixty to eighty per cent of patients with non-early stage gastric
carcinoma die of progressive disease after surgery at present
(Japanese Research Society for Gastric Cancer, 1993). Selecting a
subset ofpatients who may have a worse prognosis and who could
be treated with adjuvant therapies may be clinically useful. The
need to individualize adjuvant therapy has caused an intensive
search for newer and more reliable prognostic factors (Tanigawa et
al, 1993). Recently, a number of investigations have demonstrated
that the intratumoral vessel count is the significant predictor of
overall survival in a variety of malignancies (Srivastaba et al,
1986; Weidner et al, 1991; Macchiarini et al, 1992; Weidner et al,
1992; Toi et al, 1993; Hollingsworth et al, 1995). However, little is
known of the significance of neovascularization in gastric carci-
nomas (Maeda et al, 1995). Our previous studies demonstrated the
prognostic significance of tumour vasculature in gastric carci-
nomas that had undergone curative resection (Tanigawa et al.
1996). This study of 181 patients with non-early carcinomas, in
which 62 patients had received non-curative resection only, recon-
firmed the prognostic significance of tumour vasculature. Both
univariate and multivariate analyses of our results showed that the
intratumoral vessel count was significantly predictive of overall
survival, when tested as either a continuous or dichotomous
variable. Multivariate analysis showed that, among various clini-
copathological factors, vessel count, peritoneal metastasis, haema-
togenous metastasis and venous vessel invasion were significant
and independent prognostic factors for the overall survival of
patients with non-early gastric carcinomas. At present, despite
recent advances in adjuvant therapies, few patients with peritoneal
or haematogenous metastasis can survive for more than 1 year,
indicating the strong association of both types of metastasis with
poor prognosis. In addition, the association between venous vessel
invasion of tumour cells and poor prognosis has been well
described for various malignancies including gastric carcinomas
(Noguchi, 1990; Gabbert et al, 1991). Therefore, our result that
tumour vasculature has been evaluated as an important and inde-
pendent prognostic factor is meaningful. However, there are some
practical problems in application of the microvessel count as a
prognostic parameter. The standard deviations in the vessel counts
were not small and there was some overlap between groups. As
vessel density data were obtained from just one slice of each
tumour, tumour heterogeneity also needs to be taken into account.
Thus, it should be noted that for any individual tumour the
microvessel count may not always be very reliable.
In summary, this information on tumour angiogenesis as a prog-
nostic factor in non-early gastric carcinoma patients may lead to
improved ways to identify those patients at high risk who might
benefit from adjuvant therapies. As assessment of tumour vascu-
larity by immunohistochemistry on archival paraffin-embedded
tissues can be accomplished within 48 h, it may be possible to inte-
grate into routine practice. We would also emphasize that the
quantitative determination of tumour vasculature may be impor-
tant not only for its prognostic value, but also because it may help
predict responses to angiogenesis-inhibiting agents. In fact, AGM-
1470(TNP-470), which showed promising results in reducing
tumour growth and metastasis in animal models and has a low
systemic toxicity with rare acquisition ofresistance, is under going
early-phase clinical trials (Ingber et al, 1990; Gasparini and Harris,
1994; Teicher et al, 1994). Unfavourable prognosis of patients
with advanced gastric carcinoma requires the development ofnew
therapeutic approaches. As highly vascularized gastric carcinomas
show not only significant correlation with tumour progression to
stage IV disease but also with a worse prognosis ofthe patients, it
seems reasonable to postulate that those carcinomas may be sensi-
tive to angiogenesis inhibitors given alone or in combination
with conventional anti-cancer treatments. Therefore, among the
possible biological approaches, the potent anti-angiogenesis drugs
appear promising enough to warrant clinical investigation.
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